JP2022523047A5 - - Google Patents
Info
- Publication number
- JP2022523047A5 JP2022523047A5 JP2021543183A JP2021543183A JP2022523047A5 JP 2022523047 A5 JP2022523047 A5 JP 2022523047A5 JP 2021543183 A JP2021543183 A JP 2021543183A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2022523047 A5 JP2022523047 A5 JP 2022523047A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- human
- antigen
- antibody
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305086 | 2019-01-23 | ||
| EP19305086.1 | 2019-01-23 | ||
| PCT/EP2020/051667 WO2020152290A1 (en) | 2019-01-23 | 2020-01-23 | Cd31 competitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523047A JP2022523047A (ja) | 2022-04-21 |
| JP2022523047A5 true JP2022523047A5 (cg-RX-API-DMAC7.html) | 2023-02-01 |
Family
ID=65409014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543183A Pending JP2022523047A (ja) | 2019-01-23 | 2020-01-23 | Cd31競合剤およびその使用 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943505A1 (en) | 2020-07-22 | 2022-01-26 | Encefa | Cd38-binding cd31 peptides and uses thereof |
| CN117567594B (zh) * | 2023-11-30 | 2025-02-07 | 北京博奥森生物技术有限公司 | 一种模拟cd31线性分子抗原性的分支多肽制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| ES2642787T3 (es) | 2005-10-21 | 2017-11-20 | Lfb Usa, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| AU2009303526B2 (en) | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| FR3003171B1 (fr) | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| KR102770106B1 (ko) * | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
-
2020
- 2020-01-23 CN CN202080023098.6A patent/CN113614107A/zh active Pending
- 2020-01-23 MX MX2021008672A patent/MX2021008672A/es unknown
- 2020-01-23 US US17/425,022 patent/US20220089765A1/en not_active Abandoned
- 2020-01-23 WO PCT/EP2020/051667 patent/WO2020152290A1/en not_active Ceased
- 2020-01-23 JP JP2021543183A patent/JP2022523047A/ja active Pending
- 2020-01-23 EP EP20701759.1A patent/EP3914616A1/en not_active Withdrawn
- 2020-01-23 AU AU2020211728A patent/AU2020211728A1/en not_active Abandoned
- 2020-01-23 CA CA3127520A patent/CA3127520A1/en active Pending
- 2020-01-23 KR KR1020217026266A patent/KR20210119448A/ko not_active Ceased
- 2020-01-23 BR BR112021014574-5A patent/BR112021014574A2/pt not_active IP Right Cessation
- 2020-01-23 SG SG11202107941TA patent/SG11202107941TA/en unknown
-
2021
- 2021-07-19 IL IL284962A patent/IL284962A/en unknown
- 2021-07-21 ZA ZA2021/05154A patent/ZA202105154B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7027482B2 (ja) | Gタンパク質共役受容体を標的化する抗体および使用の方法 | |
| JP7019198B2 (ja) | 補体関連疾患の予防及び治療のためのc5抗体及び方法 | |
| JP7719897B2 (ja) | Tslp関連疾患に対する治療薬の開発及び用途 | |
| JP2018138035A (ja) | 静電的ステアリング(electrostatic steering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 | |
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| CN111320693B (zh) | 抗EphA4抗体 | |
| WO2019228405A1 (zh) | 一种自免疫抑制剂及其应用 | |
| CN104203977A (zh) | 结合肽聚糖识别蛋白1的抗体 | |
| RU2004121673A (ru) | Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей | |
| CN113906050B (zh) | 抗EphA4抗体 | |
| JP2022542884A5 (cg-RX-API-DMAC7.html) | ||
| KR20120056800A (ko) | 글루글루카곤 수용체에 대한 항체와 이의 사용 | |
| JP2025134864A5 (cg-RX-API-DMAC7.html) | ||
| WO2016119523A1 (zh) | 全人源her2抗体的突变抗体及其编码基因和应用 | |
| US20240392001A1 (en) | Lilrb2-specific monoclonal antibodies and methods of their use | |
| JP7796049B2 (ja) | 抗EphA4抗体 | |
| RU2021124077A (ru) | Конкурент за связывание с антителом CD31 и его применение | |
| JP7839108B2 (ja) | 筋萎縮性側索硬化症の治療用医薬組成物 | |
| RU2816371C2 (ru) | АНТИТЕЛО К EphA4 | |
| KR20100021657A (ko) | 프로테아제 활성화된 수용체-1 (par1)의 길항제 항체 | |
| HK40105878A (en) | Novel anti-masp-2 antibodies | |
| JP2024541576A (ja) | 新規特異的アンタゴニスト抗SIRPg抗体 | |
| HK40092741A (en) | Anti-epha4 antibody | |
| CN119585311A (zh) | 结合大麻素受体cb1的抗体及其用途 | |
| CA3294208A1 (en) | Anti-cd200r1 antibody and use thereof |